

People

Appointments

Abingworth appoints Sarah Shackelton

Abingworth Management (<http://www.abingworth.com>), the life sciences venture capital group, has appointed Sarah Shackelton to expand its relationships with key industry executives and entrepreneurs and to assist its portfolio companies with their recruitment needs. Shackelton has significant international business experience including senior level executive search experience in the life sciences area.

'This is an important strategic role for Abingworth' said Stephen Bunting, Managing Director at Abingworth. 'People are the most important component of any investment and we intend to take a more systematic approach to identify the best. Sarah has broad business experience and very strong skills in matching needs with people. We believe she will give Abingworth a true cutting edge in making connections with the best executives in the industry.'

Abingworth is a key venture capital investor, specializing in unquoted life science and biomedical companies. It has backed more than 80 life science/medical firms, most of which have gone public or been acquired.

Phaeton appoints Shohré Nabahi as new Operations Director

Drug-delivery problem-solver Phaeton Research (<http://www.phaetonresearch.com>), based in Nottingham, UK, has announced the appointment of Shohré Nabahi as its new Operations Director.

The company, re-launched during the Summer of 2003 and part of Prophilian Group, which also includes niche Phase I/IIa CRO Pharmaceutical Profiles (<http://www.pharmprofiles.com>), specializes in developing innovative solutions for difficult molecules via customised advanced drug-delivery technologies.

Nabahi will be responsible for providing direction to Phaeton's Pharmaceutical R&D group, which is involved in developing products from concept to use in Phase I clinical studies. She brings a wealth of expertise to the young company and has

also had several patents published in drug delivery and improved solubility of active molecules.

Phaeton Research, which owns the intellectual property rights to the Enterion™ drug-delivery capsule, believes there are a number of existing compounds that will work better with the appropriate new drug delivery technology to provide once-a-day-dosing, even where significant obstacles exist, such as the need for gastroretention.

Nabahi joins Phaeton Research from the Medicines and Healthcare Products Regulatory Agency (MHRA), an Executive Agency of the UK Department of Health. Before that she held senior development positions with Hoechst Marion Roussel (Swindon, UK) and was Director of Pharmaceutical Sciences with Powderject Technologies (Oxford, UK).

Cylene Pharmaceuticals announces new VP of Clinical Operations

Cylene Pharmaceuticals (<http://www.cylenepharma.com>), an oncology drug-discovery and development company, has announced that John K.C. Lim has joined the company as Vice President of Clinical Operations. Lim brings to Cylene >15 years of experience in clinical research and new drug development, principally in the oncology and biotechnology arenas, according to William Rice, President and CEO of Cylene.

'We are extremely pleased to have Dr Lim join Cylene,' said Rice. 'John will team up with Cylene co-founder Dr Daniel Von Hoff for the strategic design and execution of our preclinical and clinical development programs, including our recently selected clinical candidate, CX3543.'

Lim joined Cylene from US Oncology Research, where he was the Vice President for Research Operations. US Oncology, the country's premier cancer care services company, has contributed to the development and approval of 18 new cancer agents over the past decade. Prior to joining US Oncology, Lim held senior operations positions at Covance and Quintiles, and was active in the development of new drugs from early phase trials through post marketing research.

Cylene Pharmaceuticals is dedicated to the discovery, development and

commercialization of first-in-class small molecule drugs, with a particular emphasis in oncology. Its pipeline is led by CX3543, a *c-Myc/VEGF* oncogene inhibitor currently in preclinical development that demonstrates potent *in vivo* efficacy in xenograft models of human solid tumors.

BioPoint Solutions appoints Karen Moore as Chief Scientific Officer

BioPoint Solutions (<http://www.biopointsolutions.com>), a provider of technology solutions and professional services for the biotechnology and pharmaceutical industries, has announced the appointment of Karen Moore as Chief Science Officer. Moore will be responsible for overseeing the practical application of the company's flagship data-management and workflow enforcement solution, DiscoverTrac™, and related service offerings.

BioPoint Solutions CEO, Elery LeBlanc, said, 'We are extremely pleased that Dr Moore has joined the BioPoint team. Dr Moore is a proven executive with a distinguished career integrating science, business, and technology, gaining valuable insight into issues affecting everyday workplace processes in the BioPharma environment.'

Moore comes to BioPoint Solutions with >22 years experience in the life sciences and their practical application to medicine and the pharmaceutical industry. Most recently, she was a consultant for Etiologics, a UK-based biotechnology company, where she played a key role in the company's expansion to the USA. Previously, Moore was Chief Science Officer and a co-founder of Hypnion, a biotechnology company dedicated to developing innovative therapies for sleep disorders.

With >60 scientific publications, Moore has been instrumental in the design of laboratory support IT solutions. This experience has contributed significantly to BioPoint Solutions' flagship product, DiscoverTrac™, which enables users to validate, track and report on critical laboratory management activity during the discovery and pre-clinical drug development process.

People was written by
Matthew Thorne